Qian Jiang
Peking University People's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Qian Jiang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:57 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07925190 · A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsBeijing InnoCare Pharma Tech Co., Ltd. · not yet recruiting · Acute Myeloblastic Leukaemia · principal investigator
- Ph3NCT07407660 · Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus VenetoclaxPeking University People's Hospital · not yet recruiting · Acute Myeloid Leukemia · principal investigator
- N/ANCT07383298 · Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang · enrolling by invitation · Chronic Myeloid Leukemia · principal investigator
- Ph2NCT06453902 · TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) PatientsShenzhen TargetRx Co., Ltd. · recruiting · Chronic Myeloid Leukemia, Accelerated Phase CML · principal investigator
- N/ANCT06390306 · The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPPeking University People's Hospital · recruiting · Chronic Myeloid Leukemia · principal investigator
- Ph1NCT05434312 · TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) PatientsShenzhen TargetRx Co., Ltd. · active not recruiting · Chronic Myelogenous Leukemia · principal investigator
- Ph1/Ph2NCT05309213 · Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaBeijing Immunochina Medical Science & Technology Co., Ltd. · unknown · Leukemia · principal investigator
- Ph1NCT03882281 · Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid LeukemiaAscentage Pharma Group Inc. · completed · Chronic Myeloid Leukemia, Chronic Phase · principal investigator
- Ph2NCT03883100 · A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationAscentage Pharma Group Inc. · unknown · Chronic Myeloid Leukemia - Accelerated Phase · principal investigator
- Ph2NCT03883087 · A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I MutationAscentage Pharma Group Inc. · unknown · Chronic Myeloid Leukemia, Chronic Phase · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 23 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:57 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- 653 citationsRCR 27.7
- 298 citationsRCR 8.6
- Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.Am J Hematol · 2021138 citationsRCR 7.7
- 106 citationsRCR 2.8
- 64 citationsRCR 1.8
- Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.Eur J Immunol · 202043 citationsRCR 1.7
- Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.Clin Cancer Res · 201939 citationsRCR 1.7
- 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).Blood Cancer J · 202136 citationsRCR 1.5
- 26 citationsRCR 1.3
- The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.Leuk Res · 201818 citationsRCR 0.8